New therapeutic agents for chronic hepatitis B
M Brahmania, J Feld, A Arif… - The Lancet Infectious …, 2016 - thelancet.com
The treatment goal for chronic hepatitis B is true eradication of the hepatitis B virus, but this
is rarely achieved with first-line treatment regimens because of an inability to disrupt …
is rarely achieved with first-line treatment regimens because of an inability to disrupt …
New paradigms in hepatitis B management: only diamonds are forever
CS Coffin, SS Lee - British Medical Bulletin, 2015 - academic.oup.com
Introduction The hepatitis B virus (HBV) causes chronic hepatitis B (CHB) in∼ 350 million
people worldwide who have an increased risk of end-stage liver disease and/or …
people worldwide who have an increased risk of end-stage liver disease and/or …
Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes
D Yu, M Zhao, L Dong, L Zhao, M Zou… - Drug design …, 2016 - Taylor & Francis
Type III interferons (IFNs)(also called IFN-λ: IFN-λ1, IFN-λ2, IFN-λ3, and IFN-λ4) are critical
players in the defense against viral infection of mucosal epithelial cells, where the activity of …
players in the defense against viral infection of mucosal epithelial cells, where the activity of …
How to achieve immune control in chronic hepatitis B?
MJH van Campenhout, HLA Janssen - Hepatology international, 2015 - Springer
Chronic hepatitis B infection remains a major global health problem despite the existence of
an effective vaccine. The current treatment options are either nucleos (t) ide analog therapy …
an effective vaccine. The current treatment options are either nucleos (t) ide analog therapy …
[引用][C] Treatment of hepatitis B
HLA Janssen, J Reijnders, M Sonneveld - Zakim and Boyer's Hepatology, 2018 - Elsevier